UK Approves First Step Towards Treating Alzheimer’s Disease with Lecanemab

for pregnant women, healthcare workers, childcare workers, and people over 65. Dr. Britton also suggests that anyone who hasn’t been vaccinated in the last fve to 10 years should consider getting a booster, as the risk of whooping cough is expected to persist for several more months.

Identifying Whooping Cough

Distinguishing whooping cough from other respiratory illnesses can be diffcult, as the early stages often resemble a common cold or fu.

The classic symptom of whooping cough is a severe, rapid cough that can be followed by a “whooping” sound as the person gasps for air. However, this distinctive cough may not appear until several days into the illness. Testing is the most reliable way to diagnose whooping cough, especially in young children, and is recommended by health experts.

As the outbreak continues, health authorities are urging Australians to remain vigilant, get vaccinated, and seek medical advice if they suspect they or their children may have whooping cough.

Dementia Australia has welcomed the recent approval of Lecanemab by the UK’s Medicines and Healthcare Products Regulatory Agency, marking a signifcant milestone in the treatment of Alzheimer’s disease. The drug, which is currently under evaluation by the Therapeutic Goods Administration in Australia, has already been approved for use in several countries, including the USA, Japan, China, South Korea, and Israel.

Professor Christopher Rowe, Director of the Australian Dementia Network (ADNeT), praised the UK’s decision, emphasizing its importance despite the drug not being a cure. “This is an exciting and historic frst step towards reducing the enormous impact of Alzheimer’s disease on individuals, families, and health and aged care services,”

Professor Rowe stated. He highlighted that Lecanemab, developed by Eisai, slows the progression of early

Alzheimer’s symptoms by removing amyloid plaques from the brain, which are key contributors to the disease.

While the UK regulator approved Lecanemab, the National Institute for Health and Care Excellence (NICE) has released draft guidance suggesting it should not be provided through the UK’s National Health Service (NHS).

Dementia Australia CEO, Professor Tanya Buchanan, expressed optimism about the potential approval of Lecanemab in Australia. “This treatment, though not suitable for everyone, represents a new hope for those impacted by Alzheimer’s disease. We look forward to Australians having the option to access Lecanemab if clinically appropriate,” Professor Buchanan said. She added that while Lecanemab is not a cure, it is an important frst step towards developing effective treatments for Alzheimer’s disease.

Bowen Therapy

GENTLE, SAFE & VERY EFFECTIVE PAIN RELIEF

For all your aches, pains, strains and migraines THINK BOWEN THERAPY (THE AUSSIE THERAPY)

Practicing Bowen Therapy for the past 27 years